461 related articles for article (PubMed ID: 27166999)
21. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-409-3p regulates cell invasion and metastasis by targeting ZEB1 in breast cancer.
Ma Z; Li Y; Xu J; Ren Q; Yao J; Tian X
IUBMB Life; 2016 May; 68(5):394-402. PubMed ID: 27079864
[TBL] [Abstract][Full Text] [Related]
23. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
[TBL] [Abstract][Full Text] [Related]
24. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
25. Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell aggressiveness.
Matsushita R; Yoshino H; Enokida H; Goto Y; Miyamoto K; Yonemori M; Inoguchi S; Nakagawa M; Seki N
Oncotarget; 2016 May; 7(19):28460-87. PubMed ID: 27072587
[TBL] [Abstract][Full Text] [Related]
26. CircSETDB1 knockdown inhibits the malignant progression of serous ovarian cancer through miR-129-3p-dependent regulation of MAP3K3.
Li B; Zhang L
J Ovarian Res; 2021 Nov; 14(1):160. PubMed ID: 34789310
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of microRNA-21-3p suppresses proliferation as well as invasion and induces apoptosis by targeting RNA-binding protein with multiple splicing through Smad4/extra cellular signal-regulated protein kinase signalling pathway in human colorectal cancer HCT116 cells.
Hou N; Guo Z; Zhao G; Jia G; Luo B; Shen X; Bai Y
Clin Exp Pharmacol Physiol; 2018 Jul; 45(7):729-741. PubMed ID: 29542167
[TBL] [Abstract][Full Text] [Related]
28. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.
Chao A; Lin CY; Lee YS; Tsai CL; Wei PC; Hsueh S; Wu TI; Tsai CN; Wang CJ; Chao AS; Wang TH; Lai CH
Oncogene; 2012 Feb; 31(6):764-75. PubMed ID: 21725366
[TBL] [Abstract][Full Text] [Related]
29. MiR-374b-5p-FOXP1 feedback loop regulates cell migration, epithelial-mesenchymal transition and chemosensitivity in ovarian cancer.
Li H; Liang J; Qin F; Zhai Y
Biochem Biophys Res Commun; 2018 Oct; 505(2):554-560. PubMed ID: 30274777
[TBL] [Abstract][Full Text] [Related]
30. MiR-574-3p exerts as a tumor suppressor in ovarian cancer through inhibiting MMP3 expression.
Zheng J; Zhou Y; Li XJ; Hu JM
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6839-6848. PubMed ID: 31486483
[TBL] [Abstract][Full Text] [Related]
31. MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells.
Kleemann M; Schneider H; Unger K; Sander P; Schneider EM; Fischer-Posovszky P; Handrick R; Otte K
Sci Rep; 2018 Jun; 8(1):9020. PubMed ID: 29899543
[TBL] [Abstract][Full Text] [Related]
32. miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.
Shan W; Li J; Bai Y; Lu X
Tumour Biol; 2016 Apr; 37(4):5203-11. PubMed ID: 26553360
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
Cheng W; Liu T; Wan X; Gao Y; Wang H
FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G
Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362
[TBL] [Abstract][Full Text] [Related]
36. MiR-219-5p inhibits growth and metastasis of ovarian cancer cells by targeting HMGA2.
Xing F; Song Z; He Y
Biol Res; 2018 Nov; 51(1):50. PubMed ID: 30474570
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2.
Xia B; Lin M; Dong W; Chen H; Li B; Zhang X; Hou Y; Lou G
J Biochem Mol Toxicol; 2018 Aug; 32(8):e22168. PubMed ID: 30004169
[TBL] [Abstract][Full Text] [Related]
38. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
39. Mir-30b-3p affects the migration and invasion function of ovarian cancer cells by targeting the CTHRC1 gene.
Li Y; Zhou J; Wang J; Chen X; Zhu Y; Chen Y
Biol Res; 2020 Mar; 53(1):10. PubMed ID: 32156314
[TBL] [Abstract][Full Text] [Related]
40. Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.
Liu S; Fang Y; Shen H; Xu W; Li H
Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):756-62. PubMed ID: 23824073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
